FcRider-based Expression and Delivery of Stable Env Immunogens for HIV Vaccines
$299,998N43FY2022AINIH
Antagen Pharmaceuticals, Inc., Boston MA
Investigators
Abstract
Novel Platforms for Delivery and/or Expression of HIV Env Immunogens for HIV Vaccines: Efforts towards the development of an efficacious HIV vaccine have focused on improvements in the design of the HIV envelope (Env) immunogen for induction and generation of broadly neutralizing antibody (bNAb) responses and novel platforms for immunogen delivery. The goal of this program is to develop an HIV vaccine platform for delivery of HIV Env immunogens that induce bnAbs and to demonstrate that the vaccine platform/immunogen proposed will elicit a strong and durable NAb HIV Env response.
View original record on NIH RePORTER →